POH18 Dilemmas and Debates in Derm
DESCRIPTION
The dermatology residency selection process is rapidly evolving with changes in standardized examination scoring, holistic review practices, preference signaling, letters of recommendation, and the increasing visibility of applicants’ digital identities. This session will explore the ethical challenges of selecting future dermatologists while balancing excellence, equity, diversity, transparency, and fairness. Participants will examine potential biases and limitations within current selection methods, discuss responsible approaches to evaluating professionalism and learner errors, and identify strategies to foster a just, accountable, and inclusive educational culture that supports the development of the next generation of dermatologists.
LEARNING OBJECTIVES
Examine the ethical challenges and evolving practices in dermatology residency selection.
Evaluate strategies to promote equity, diversity, transparency, and fairness in recruitment and ranking processes.
Apply principles of professionalism, accountability, and compassionate mentorship in evaluating applicants and trainees.
SCHEDULE
7:30 AM
Ethics in Dermatology Residency Recruitment and Selection
DIRECTOR
Cheryl M. Burgess, MD, FAAD
Center for Dermatology and Dermatologic Surgery; The George Washington University Dept of Dermatology
SPEAKER
Stephanie Mengden, MD, FAAD
DISCLOSURES
Cheryl M. Burgess, MD, FAAD
Aerolase – Investigator(Equipment); Allergan, Inc. – Investigator(Grants/Research Funding), Stockholder(Stock); Ipsen – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Investigator(Grants/Research Funding); L'Oreal Dermatological Beauty – Investigator(Grants/Research Funding); Merz Aesthetics – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Prollenium – Investigator(Grants/Research Funding); Revance Therapeutics, Inc. – Investigator(Grants/Research Funding); TEOXANE Laboratories – Investigator(Grants/Research Funding);
Stephanie Mengden, MD, FAAD
No financial relationships exist with ineligible companies.